Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAPK1 | P53355 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13170603 | 0.78 | DAPK1 (0.31) | DAPK1 | |
| SCHEMBL17281097 | 0.66 | — | — | |
| SCHEMBL18512535 | 0.65 | DAPK1 (0.36) | DAPK1 | |
| SCHEMBL2757598 | 0.64 | RAB9A (0.33) | — | |
| SCHEMBL2757589 | 0.63 | GAA (0.40) | — | |
| SCHEMBL13170606 | 0.62 | KDM4E (0.38) | — | |
| SCHEMBL19366633 | 0.59 | ALDH1A1 (0.41) | DAPK1 | |
| SCHEMBL18512527 | 0.59 | DCTPP1 (0.33) | DAPK1 | |
| SCHEMBL27405153 | 0.59 | ADORA1 (0.41) | DAPK1 | |
| SCHEMBL13316180 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9850214-B2 | Inhibitors of NEDD8-activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170136024-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. | 2017-05-18 | — | — | US | disclosed |
| US-20150011572-A1 | INHIBITORS OF NEDD8-ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-8809356-B2 | Inhibitors of NEDD8-activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20130289037-A1 | INHIBITORS OF E1 ACTIVTING ENZYMES | MILLENNIUM PHARM INC (US) | 2013-10-31 | — | — | US | disclosed |
| US-20130165457-A9 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20120258977-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120258927-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENIUM PHARMACEUTICALS, INC. (US) | 2012-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258977-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | DAPK1 1782/4885 |
| US-20150011572-A1 | INHIBITORS OF NEDD8-ACTIVATING ENZYME | NEDD8, NAE1, UBA3 | DAPK1 1622/4885 |
| US-20120258927-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | DAPK1 1782/4885 |
| US-20170136024-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | DAPK1 1782/4885 |
| US-20130165457-A9 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | DAPK1 1782/4885 |
| US-20130289037-A1 | INHIBITORS OF E1 ACTIVTING ENZYMES | RNASE1, ECE1, CES1 | DAPK1 1945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.